TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10585981
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg of MPH received twice (7:30 AM and 11:30 AM) with 0.15 mg/kg received at 3:30 PM
Study: 10585981
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg of MPH at 3:30 PM
Study: 1846848
Drug: Cisplatin 3.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 3.2 mg/m2/24 hr with 66 Gy in 33 fractions over 6 1/2 weeks for NSCLC
Study: 1846848
Drug: Cisplatin 4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 4.0 mg/m2/24 hr with 45 Gy in 25 fractions over 5 weeks for rectal carcinoma
Study: 1846848
Drug: Cisplatin 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 5.0 mg/m2/24 hr
Study: 1846848
Drug: Further external
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Further external beam therapy up to 59.4 Gy
Study: 1846848
Drug: Toxicity related
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toxicity related to cisplatin dose
Study: 1846848
Drug: Maximum tolerated
Normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maximum tolerated dose
Study: 27040515
Drug: BNP tertile
Normalized name: BNP
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BNP tertile 1 (BNP ≤ 376 pg/mL)
Study: 27040515
Drug: BNP tertile
Normalized name: BNP
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BNP tertile 2 (BNP 377 to 792 pg/mL)
Study: 27040515
Drug: BNP tertile
Normalized name: BNP
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BNP tertile 3 (BNP ≥ 793 pg/mL)
Study: 24339313
Drug: Oral hygienic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygienic care program (OHCP) including tooth brushing with an inter-dental brush and tongue cleaner, and cleaning with chlorhexidine, administered once per day for a mean duration of 2.2 weeks.
Study: 21288666
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg DM Se
Study: 21288666
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg DM Se
Study: 21288666
Drug: 4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/kg DM Se
Study: 21288666
Drug: 0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg/kg DM Se (Control)
Study: 17503747
Drug: Induction/maintenance (IM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction/maintenance (IM) therapy: two NRTIs + one NNRTI + one protease inhibitor for 24-32 weeks, followed by two NRTIs + NNRTI
Study: 17503747
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (ST): two NRTIs + NNRTI
Study: 17503747
Drug: Induction/maintenance (IM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction/maintenance (IM) therapy
Study: 15201565
Drug: Sildenafil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (50 mg, flexible)
Study: 9554347
Drug: Alprostadil-prazosin combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprostadil-prazosin combination (500/2,000 microg)
Study: 29344729
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (NaHCO3) supplementation (0.3 g kg bm-1)
Study: 29344729
Drug: Placebo (sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sodium chloride, 0.21 g kg bm-1)
Study: 27315514
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg DCS administered 1 hr prior to the final three sessions of CBT
Study: 27315514
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo administered 1 hr prior to the final three sessions of CBT
Study: 25661281
Drug: Tiotropium 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 5 μg once-daily
Study: 25661281
Drug: Tiotropium 2.5
Normalized name: TIOTROPIUM 2.5MCG/ACTUAT 60D ORAL INHL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 2.5 μg twice-daily
Study: 25661281
Drug: Tiotropium (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium (both dosing regimens)
Study: 23161599
Drug: Buprenorphine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (mean dose: 14.00 mg)
Study: 23161599
Drug: Methadone (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone (mean dose: 52.50 mg)
Study: 23161599
Drug: Escalating voucher
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating voucher incentives for drug-free urine samples (MOTHER-trial only)
Study: 23161599
Drug: Oral morphine
Normalized name: morphine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral morphine solution for neonatal abstinence syndrome treatment
Study: 21903536
Drug: Total-etch adhesive
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total-etch adhesive system with diamond bur preparation
Study: 21903536
Drug: Total-etch adhesive
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total-etch adhesive system with Er:YAG laser preparation
Study: 21903536
Drug: Self-etch adhesive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-etch adhesive system with diamond bur preparation
Study: 21903536
Drug: Self-etch adhesive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-etch adhesive system with Er:YAG laser preparation
Study: 18353012
Drug: Conventional bur
Normalized name: bur oak pollen extract
DrugBank: Quercus macrocarpa pollen (DB10738)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional bur treatment
Study: 16115991
Drug: morphine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine + ketamine (n = 8)
Study: 16115991
Drug: morphine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: morphine + placebo (n = 8)
Study: 12693594
Drug: Antibiotic sensitivity
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic sensitivity testing
Study: 2137066
Drug: Sorbinil (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorbinil (250 mg day-1)
Study: 7011622
Drug: 3 g/24
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/24 hr frusemide (sustained)
Study: 7011622
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g frusemide (single injection)
Study: 12955305
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg oxycodone
Study: 14729881
Drug: MBvO gymnastics
Approvals — FDA: no, EMA: no, PMDA: no
Description: MBvO gymnastics twice weekly (MBvO2; n = 68)
Study: 14729881
Drug: MBvO gymnastics
Approvals — FDA: no, EMA: no, PMDA: no
Description: MBvO gymnastics once weekly (MBvO1; n = 125)
Study: 11854673
Drug: Poor oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poor oral hygiene before treatment
Study: 7926910
Drug: 4-aminosalicylic acid
Normalized name: 4-aminosalicylic acid
DrugBank: Aminosalicylic acid (DB00233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-aminosalicylic acid (4-ASA) 1.5 g/d, slow release tablets
Study: 7926910
Drug: 5-aminosalicylic acid
Normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminosalicylic acid (5-ASA) 1.5 g/d, slow release tablets
Study: 3135011
Drug: Whole cell
Normalized name: pertussis, whole cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole cell pertussis vaccine (3 doses, one month apart)
Study: 31305450
Drug: fentanyl-based intravenous
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: fentanyl-based intravenous patient-controlled analgesia with low dose of ketamine (fk-IVPCA)
Study: 24107877
Drug: noojerone (memantine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: noojerone (memantine) in addition to standard therapy for 6 months
Study: 24107877
Drug: standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard therapy only
Study: 19848371
Drug: Wavefront-guided optimized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wavefront-guided optimized path difference custom aspheric treatment (OPDCAT group)
Study: 17006746
Drug: Tiotropium (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium (18 mcg)
Study: 3606915
Drug: i.v. lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. lignocaine 1.5 mg kg‐1 plus 2 mg kg‐1 h‐1
Study: 23115322
Drug: High-dose beta-blockers
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose beta-blockers
Study: 11198725
Drug: Flurbiprofen 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen 12.5 mg
Study: 12011823
Drug: Flurbiprofen 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen 5.0 mg
Study: 12011823
Drug: Flurbiprofen 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen 2.5 mg
Study: 12011823
Drug: Flurbiprofen (per
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen (per mg increase)
Study: 7914122
Drug: Proxodolol (Pd)
Normalized name: Dianeal PD-2/2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proxodolol (Pd) single dose of 0.04-0.08 g
Study: 7914122
Drug: Propranolol (Pr)
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol (Pr) single dose of 0.04-0.08 g
Study: 7914122
Drug: Proxodolol (Pd)
Normalized name: Dianeal PD-2/2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proxodolol (Pd) course treatment mean daily dose of 186 +/- 24 mg
Study: 7914122
Drug: Propranolol (Pr)
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol (Pr) course treatment mean daily dose of 182 +/- 25 mg
Study: 7914122
Drug: Proxodolol (Pd)
Normalized name: Dianeal PD-2/2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proxodolol (Pd) single dose of 0.04 g
Study: 7914122
Drug: Propranolol (Pr)
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol (Pr) single dose of 0.04 g
Study: 7914122
Drug: Proxodolol (Pd)
Normalized name: Dianeal PD-2/2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proxodolol (Pd) and Propranolol (Pr) during course therapy
Study: 3378465
Drug: Cefamandole (preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefamandole (preoperative and four postoperative doses)
Study: 3378465
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no parenteral antibiotics)
Study: 31112380
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (propofol, midazolam, or other sedatives)
Study: 19200607
Drug: Gambling Symptom
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gambling Symptom Assessment Scale (G‐SAS)
Study: 15287544
Drug: Calcium hydroxide
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium hydroxide paste with anesthetic solution
Study: 9596107
Drug: Regular inhaled
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular inhaled beta2-agonist (fenoterol) treatment
Study: 3149455
Drug: Buserelin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buserelin (200 micrograms subcutaneously daily or 400 micrograms intranasally three times daily)
Study: 29338146
Drug: High liberal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High liberal group (15 mL/kg/hr intraoperatively and 10 mL/kg/hr six hours postoperatively)
Study: 29338146
Drug: Low liberal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low liberal group (5 mL/kg/hr intraoperatively and six hours postoperatively)
Study: 29338146
Drug: Restrictive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive group (1 mL/kg/hr intraoperatively and six hours postoperatively)
Study: 23422913
Drug: BC-3781 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: BC-3781 100 mg
Study: 23422913
Drug: BC-3781 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: BC-3781 150 mg
Study: 17954698
Drug: Vancomycin 1
Normalized name: vancomycin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin 1 g every 12 h
Study: 16970093
Drug: Yuquan Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yuquan Pill (YP) 6 g four times a day for 3 months
Study: 16970093
Drug: Glucobay with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucobay with dietary and exercise therapy for 3 months (Control)
Study: 9987507
Drug: Metoclopramide 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 40 mg/day
Study: 9987507
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg/day
Study: 8846678
Drug: Insulin and
Normalized name: Isophane insulin and porcine regular insulin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin and glibenclamide
Study: 27364603
Drug: COPD Assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: COPD Assessment Test (CAT) administered at baseline, 1.5 years, and 3 years.
Study: 27364603
Drug: COPD Assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: COPD Assessment Test (CAT) administered to distinguish between exacerbation status.
Study: 27364603
Drug: COPD Assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: COPD Assessment Test (CAT) administered to different demographic groups.
Study: 20679551
Drug: Paramedic cooling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paramedic cooling with rapid infusion of 2 L of ice-cold lactated Ringer's solution
Study: 16330196
Drug: Oral montelukast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral montelukast for 4 weeks
Study: 10937516
Drug: Dilazep dihydrochloride
Normalized name: Levocetirizine Dihydrochloride
DrugBank: Dilazep (DB13715)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilazep dihydrochloride (300 mg/day)
Study: 3789755
Drug: Radiotherapy and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy and/or combination chemotherapies (ACOP, ACOP‐E and AclBEP regimens)
Study: 29304735
Drug: IV dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV dexmedetomidine 0.5 μg.kg‐1 (Group DEX, n=30)
Study: 18343242
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (30 mg nifedipine)
Study: 18343242
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (30 mg nifedipine)
Study: 9493517
Drug: Fixed-dose regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose regimen of interferon-alpha2a (3 MIU three times a week for 6 months)
Study: 9493517
Drug: Fixed-dose regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose regimen of interferon-alpha2a (3 MIU three times a week for 6 months) in non-cirrhotic patients
Study: 7982429
Drug: L-propionylcarnitine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-propionylcarnitine (1.5 g orally for 6 months)
Study: 419810
Drug: Bencyclane 100
Normalized name: bencyclane 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bencyclane 100 mg
Study: 419810
Drug: Bencyclane 200
Normalized name: bencyclane 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bencyclane 200 mg
Study: 31669451
Drug: Virtual Reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual Reality Exposure Therapy (VRE) combined with 50 mg D-Cycloserine (DCS)
Study: 31669451
Drug: Prolonged Exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged Exposure Therapy (PE) combined with 50 mg D-Cycloserine (DCS)
Study: 31669451
Drug: Placebo combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo combined with Prolonged Exposure Therapy (PE)
Study: 31669451
Drug: Placebo combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo combined with Virtual Reality Exposure Therapy (VRE)
Study: 25586864
Drug: LNG/EE patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNG/EE patch (one patch weekly for three consecutive weeks, followed by a patch-free week for 13 cycles)
Study: 25586864
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive for six cycles followed by seven LNG/EE patch cycles
Study: 21372210
Drug: Atrasentan 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrasentan 0.75 mg daily
Study: 21372210
Drug: Atrasentan 1.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrasentan 1.75 mg daily
Study: 21372210
Drug: Atrasentan 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrasentan 0.25 mg daily
Study: 17278627
Drug: All 4
Normalized name: Flex-All 454
Approvals — FDA: no, EMA: no, PMDA: no
Description: All 4 bonding agents
Study: 15144613
Drug: Concurrent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent treatment group (group A)
Study: 15144613
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment group (group B)
Study: 11473503
Drug: Moclobemide (MCB)
Normalized name: moclobemide
DrugBank: Moclobemide (DB01171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (MCB) 450-750 mg daily
Study: 11473503
Drug: Imipramine (IMI)
DrugBank: Imipramine (DB00458)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Imipramine (IMI) 150-250 mg daily
Study: 3191076
Drug: timolol administration
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: timolol administration to the normal eye
Study: 28207733
Drug: Citalopram (SSRI)
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citalopram (SSRI) administered for 2 weeks
Study: 20008622
Drug: Imatinib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 800 mg/d
Study: 21422420
Drug: Imatinib 400
Normalized name: imatinib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 400 mg/d plus interferon alfa (IFN-α)
Study: 19794004
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy including WOSCOPS
Study: 17068072
Drug: Alteplase 1
Normalized name: alteplase 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alteplase 1 mg/ml
Study: 17068072
Drug: Alteplase or
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alteplase or urokinase infusion
Study: 15502051
Drug: Oxymorphone IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymorphone IR 30 mg
Study: 15502051
Drug: Oxycodone IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone IR 10 mg
Study: 9702441
Drug: Amitriptyline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline plus sham treatment
Study: 8045488
Drug: Recombinant interferon‐alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant interferon‐alpha 2a 7.5 megaunits/m2 three times weekly for 6 mo (group 1)
Study: 2729165
Drug: Zinc supplement
Normalized name: Zinc supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplement (10 mg Zn/d as ZnSO4)
Study: 2729165
Drug: Control (boys
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (boys with hair Zn greater than 1.68 mumol/g)
Study: 18048461
Drug: Purified Vero
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified Vero cell rabies vaccine (PVRV) given at 2, 4 months and 1 year
Study: 18048461
Drug: Diphtheria, tetanus,
Normalized name: Diphtheria, Tetanus, Poliomyelitis adsorbed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphtheria, tetanus, whole‐cell pertussis and inactivated poliomyelitis vaccine (DTP‐IPV)
Study: 18048461
Drug: Purified Vero
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified Vero cell rabies vaccine (PVRV) and DTP‐IPV
Study: 16505510
Drug: rosiglitazone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosiglitazone (4 mg twice a day for 12 weeks)
Study: 14655024
Drug: Insulin +
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin + methotrexate
Study: 11389705
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (with corticosteroids)
Study: 11389705
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (with corticosteroids and azathioprine)
Study: 31719071
Drug: Perineural catheter
Normalized name: ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perineural catheter (PNC) with continuous infusion of levobupivacaine hydrochloride 0.125% for up to 5 days
Study: 29408444
Drug: l-arginine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-arginine (10 mM)
Study: 27087145
Drug: Ivermectin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (30 mg oral, once a day)
Study: 20622033
Drug: Ataluren (PTC124)
DrugBank: Ataluren (DB05016)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Ataluren (PTC124) at lower dose (4, 4, and 8 mg/kg)
Study: 20622033
Drug: Ataluren (PTC124)
DrugBank: Ataluren (DB05016)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Ataluren (PTC124) at higher dose (10, 10, and 20 mg/kg)
Study: 17558098
Drug: Tinospora cordifolia
Normalized name: tinospora cordifolia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinospora cordifolia as an adjuvant therapy
Study: 16623023
Drug: Sporal 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sporal 200 mg twice daily for 1 week
Study: 16623023
Drug: Itracon 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itracon 200 mg twice daily for 1 week
Study: 16623023
Drug: Itra 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itra 200 mg twice daily for 1 week
Study: 8682088
Drug: Immunosuppressive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive therapy plus conventional drug therapy for congestive heart failure
Study: 1320131
Drug: CAV regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAV regimen (cyclophosphamide 1000 mg/m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2 every 3 weeks)
Study: 1320131
Drug: Menogaril (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menogaril (200 mg/m2 every 4 weeks)
Study: 1320131
Drug: Salvage chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvage chemotherapy (etoposide 120 mg/m2 on days 1, 2, and 3 and cisplatin 60 mg/m2 on day 1, repeated every 3 weeks)
Study: 6325313
Drug: Preparation A
Normalized name: POVIDONE-IODINE 75 mg in 1 mL TOPICAL SOLUTION [Antiseptic Patient Preoperative Skin Preparation and Surgical Hand Scrub]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation A (bovine fibrinolysin and desoxyribonuclease, no antibiotic)
Study: 6325313
Drug: Preparation B
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation B (clostridiopeptidase and chloramphenicol)
Study: 6325313
Drug: Preparation C
Normalized name: other nasal preparation combinations in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation C (trypsin and framycetin sulphate)